Biopharmaceutical company Solvonis Therapeutics plc (LSE: SVNS) announced on Wednesday that it has appointed US-based research and investor engagement firm Water Tower Research LLC to enhance its understanding of the US market, refine its corporate profile and expand its institutional investor reach.

Under the engagement, Water Tower Research will provide research coverage and investor engagement support, including initiation reports, updates, management series content and multimedia outputs, distributed through its established network and channels.

The company expects the appointment to strengthen its insight into the evolving US regulatory, policy and capital markets landscape, which is increasingly relevant as it advances its central nervous system pipeline. This includes key programmes such as SVN-002 for alcohol use disorder, SVN-015 for stimulant addiction and SVN-114 for post-traumatic stress disorder.

Solvonis Therapeutics also aims to broaden access to US institutional investors, recognising the importance of the US as a leading capital market for innovative CNS companies. The initiative is intended to support longer-term positioning and address a perceived valuation gap relative to US-listed peers.